drugset
Drugs / pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine
last change May 2026 re-read 3 minutes ago

pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine

Vaccine

Developed for
axillary neoplasm · female breast carcinoma · Her2-receptor negative breast cancer
Investigated by
National Cancer Institute (NCI) · University of Washington · University of Wisconsin, Madison

Trials 1

today NCT02780401 · Ph 1
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02780401 Sep 2016 → Oct 2020 Her2-receptor negative breast cancer, axillary neoplasm, female breast carcinoma University of Washington Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT02780401 ↗
Modality Vaccine “Th1 selective multiantigen, polyepitope plasmid-DNA vaccine encoding segments of IGFBP-2, HER2, and IGF-IR” PMID 42082270 ↗ May 2026